Increased Expression Of ARHGAP30 Is Associated With Poor Prognosis In Patients With Clear Cell Renal Cell Carcinoma

Background: The underlying mechanism of tumorigenesis and development of clear cell renal cell carcinoma(ccRCC)remain unknown.The aim of the study was to investigate the role of Rho GTPase activating protein 30(ARHGAP30)in ccRCC and explore the relevant signaling pathways.Methods: Data of ccRCC samples from online databases the Cancer Genome Atlas and the Gene Expression Omnibus was analysed.mRNA and protein expression of ARHGAP30 were assessed both in ccRCC tissues and cell lines by quantitative realtime polymerase chain reaction and Western blot.Cox proportional hazard regression model and the Kaplan-Meier method were used to determine the clinical significance of ARHGAP30.Gene Set Enrichment Analysis(GSEA)was conducted to explore the relevant signaling pathways.Results: mRNA and protein expression of ARHGAP30 were both upregulated in ccRCC tissues and cell lines.Besides,multivariate analysis revealed that age(HR,1.031;95%CI,1.018-1.044;P < 0.001),American Joint Committee on Cancer(AJCC)stage(HR,4.470;95%CI,3.308-6.041;P<0.001),and the expression of ARHGAP30(HR,1.342;95%CI,1.006-1.791;P=0.045)were independent prognostic factors for OS in patients with ccRCC.Kaplan-Meier analysis showed that ccRCC patients with high ARHGAP30 expression had a shorter OS than those with low ARHGAP30 expression(P=0.015),especially in the subgroups of age ≤ 65 years(P=0.028)and AJCC stage I and II(P=0.015).GSEA showed that ARHGAP30 may promote the tumorigenesis and development of ccRCC via the Janus kinase/signal transducer and activator of transcription(JAK/STAT)signaling pathway.Conclusion: In conclusion,ARHGAP30 may act as a promoter in the tumorigenesis and development of ccRCC via the JAK/STAT signaling pathway.ARHGAP30 may be a new potential therapeutic target for ccRCC in the future.